Recent research from the National Institutes of Health (NIH) suggests that VIP36 could be a promising, non-addictive alternative to opioids for treating both acute and chronic pain.
The drug works by targeting the body’s cannabinoid receptor type 1 (CB1), which restricts CB1 agonists from minimizing arrestin recruitment. CB1 receptors are widely distributed throughout the body, particularly in the brain's pain circuitry.
“The current opioid overdose epidemic highlights the urgent need